All articles by
ExcellGene SA and Cytovance Biologics Join Forces to Transform Large Molecule Biologics Development and Manufacture
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces…
LEO Pharma’s Enstilar meets primary endpoint in Phase 3 plaque psoriasis trial
Medical dermatology company LEO Pharma said that Enstilar (LEO 90100) has achieved both primary and secondary endpoints in a Phase…
BioVersys expands partnership with GSK for TB drug candidate alpibectir
BioVersys, a clinical-stage biopharmaceutical firm, and British drugmaker GSK have expanded their partnership to expedite the clinical development of alpibectir…
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA
CytomX Therapeutics, a leader in the field of masked, conditionally activated biologics, today announced that it has entered into a…
EyePoint’s Duravyu fails to meet primary endpoint in Phase 2 NPDR trial
EyePoint Pharmaceuticals said that the Phase 2 PAVIA clinical trial evaluating Duravyu (vorolanib intravitreal insert) in patients with non-proliferative diabetic…
Gossamer Bio and Chiesi sign deal for Seralutinib development
Biopharmaceutical company Gossamer Bio and Italian pharma Chiesi Group have announced a potential $486m global collaboration and licensing deal to…
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative…
Boehringer Ingelheim’s antibody meets primary safety endpoints in DMI trial
Boehringer Ingelheim has announced its antibody BI 764524 has shown positive results in the HORNBILL Phase 1/2a trial of patients…
Poseida secures cell therapies deal worth up to $600m with Xyphos
Poseida Therapeutics has secured a research collaboration and license agreement worth up to $600m with Xyphos Biosciences to develop allogeneic…
BridgeBio launches BridgeBio Oncology Therapeutics with $200m funding
US-based biopharmaceutical company BridgeBio Pharma has launched a new oncology-focused firm dubbed BridgeBio Oncology Therapeutics (BBOT) with $200m of private…